Roivant Sciences Ltd. $ROIV Shares Bought by Universal Beteiligungs und Servicegesellschaft mbH

Key Points

• Universal Beteiligungs raised its stake in Roivant by 90.9% in Q4 to 80,561 shares (worth about $1.75M), and institutional investors now own roughly 64.76% of the company.
• Significant insider selling: insiders disposed of 5,085,398 shares valued at about $139.2M over the last 90 days, leaving insiders with roughly 10.8% ownership.
• Wall Street is broadly bullish on ROIV with a consensus rating of "Moderate Buy" and an average target of $30.55 (several firms raised targets, Piper Sandler to $40); the stock recently opened at $27.83 and the company has a market cap of about $19.9B.

Universal Beteiligungs und Servicegesellschaft mbH raised its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 90.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 80,561 shares of the company's stock after acquiring an additional 38,354 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH's holdings in Roivant Sciences were worth $1,746,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the business. Penn Davis Mcfarland Inc. raised its position in shares of Roivant Sciences by 10.1% during the 3rd quarter. Penn Davis Mcfarland Inc. now owns 1,862,088 shares of the company's stock worth $28,173,000 after purchasing an additional 170,456 shares during the last quarter. TD Asset Management Inc lifted its position in shares of Roivant Sciences by 94.7% in the third quarter. TD Asset Management Inc now owns 316,200 shares of the company's stock valued at $4,784,000 after acquiring an additional 153,800 shares in the last quarter. Neo Ivy Capital Management boosted its stake in shares of Roivant Sciences by 229.6% during the third quarter. Neo Ivy Capital Management now owns 237,392 shares of the company's stock valued at $3,592,000 after acquiring an additional 165,362 shares during the last quarter. New York State Common Retirement Fund increased its position in Roivant Sciences by 25.4% during the 3rd quarter. New York State Common Retirement Fund now owns 229,037 shares of the company's stock worth $3,465,000 after purchasing an additional 46,344 shares in the last quarter. Finally, HighVista Strategies LLC raised its stake in Roivant Sciences by 61.4% in the 3rd quarter. HighVista Strategies LLC now owns 98,858 shares of the company's stock valued at $1,496,000 after purchasing an additional 37,590 shares during the last quarter. Institutional investors own 64.76% of the company's stock.

Roivant Sciences Stock Down 2.5%

Roivant Sciences stock opened at $27.83 on Friday. The firm has a fifty day moving average of $28.30 and a 200-day moving average of $23.90. Roivant Sciences Ltd. has a 52-week low of $10.58 and a 52-week high of $30.33. The firm has a market capitalization of $19.92 billion, a P/E ratio of -23.79 and a beta of 1.14.

Insider Buying and Selling

In other Roivant Sciences news, Director Daniel Allen Gold sold 425,000 shares of the company's stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $26.67, for a total value of $11,334,750.00. Following the completion of the transaction, the director owned 15,928,113 shares in the company, valued at $424,802,773.71. This represents a 2.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mayukh Sukhatme sold 339,441 shares of Roivant Sciences stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $26.47, for a total transaction of $8,985,003.27. Following the sale, the insider owned 19,148,664 shares in the company, valued at $506,865,136.08. This represents a 1.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 5,085,398 shares of company stock valued at $139,215,946 over the last ninety days. Insiders own 10.80% of the company's stock.

Wall Street Analysts Forecast Growth

ROIV has been the topic of several recent analyst reports. Piper Sandler upped their price objective on shares of Roivant Sciences from $22.00 to $40.00 and gave the company an "overweight" rating in a research note on Thursday, April 16th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. Guggenheim raised their price target on Roivant Sciences from $28.00 to $30.00 and gave the stock a "buy" rating in a research note on Monday, February 9th. Sanford C. Bernstein started coverage on Roivant Sciences in a report on Friday, March 20th. They issued an "outperform" rating and a $35.00 price target for the company. Finally, Citigroup increased their price objective on shares of Roivant Sciences from $26.00 to $35.00 and gave the stock a "buy" rating in a report on Tuesday, February 10th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $30.55.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.